Treatment Considerations in MDS from ASCO/EHA 2022

 

EHA 2022 Conference Coverage
D

Lecture Summary - EHA 2022 CD47 Targeting in HR-MDS: Surveying Clinical Data for Magrolimab

By EHA 2022 Conference Coverage FEATURING David Sallman
By EHA 2022 Conference Coverage FEATURING David Sallman
15 views
August 4, 2022
0 Comments
Login to view comments. Click here to Login
Treatment Considerations in MDS from ASCO/EHA 2022
24:29
MDS Foundation

Immunotherapy Strategies in MDS

Feat. S. Gill
24:49
MDS Foundation

The Evolving Use of Immune Checkpoint Blockade in Management of MDS

Feat. A. Zeidan
22:43
Penn Medicine Abramson Cancer Center

Highlights in the Prognostication of MDS This Year

Feat. S. McCurdy
20:10
Rush University Medical Center

Novel Agents for MDS

Feat. S. Dinner
04:48
EHA 2022 Conference Coverage

EHA 2022 Magrolimab in Combination With Azacitidine for Untreated Hi…

Feat. D. Sallman
10:02
Gautham Borthakur

Anti-CD47 Therapy in MDS

15:31
Yale Cancer Center

The Importance of the TP53 Evaluation in the Management of HR-MDS

Feat. R. Shallis
09:58
Penn Medicine Abramson Cancer Center

EHA and ASCO 2022 Penn Medicine Updates on AML and MDS

Feat. K. Pratz
20:03
SOHO Italy 1st Clinical and Biological School of CAR-T

T, NK, and Macrophage-Based Therapies in AML

Feat. N. Daver
39:34
MDS Foundation

Making Heads and Tails of NGS Printouts and Their Role in MDS

Feat. B. Ebert
16:58
MDS Foundation

Mechanisms and Predictors of Drug Resistance in HR-MDS: Intolerance …

Feat. M. Sekeres
27:27
Moffitt Cancer Center's 17th Annual Clinical Breakthroughs & Challenges in Hematologic Malignancies

2022 State of the Art Frontline Management of the HR-MDS

Feat. R. Komrokji
06:24
EHA 2022 Conference Coverage

EHA 2022 CD47 Targeting in HR-MDS: Surveying Clinical Data for Magro…

Feat. D. Sallman
30
EHA 2022 Conference Coverage

Lecture Summary - EHA 2022 CD47 Targeting in HR-MDS: Surveying Clini…

Feat. D. Sallman
35:36
MDS Foundation

Optimizing Transfusion Support for Patients With MDS

Feat. Y. Lin